Company Snapshot: KemPharm, Inc.

KMPH
Last	Change	Volume	High	Low

Company Overview

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.

Client News

1. Aug 11 2022 KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
2. Aug 11 2022 KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
3. Aug 9 2022 KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
4. Aug 9 2022 KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications